Synthesis, biological evaluation, and molecular modeling of (E)-2-aryl-5-styryl-1,3,4-oxadiazole derivatives as acetylcholine esterase inhibitors

[1]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[2]  P. Sharma,et al.  Synthesis and evaluation of substituted diphenyl-1,3,4-oxadiazole derivatives for central nervous system depressant activity , 2012, Organic and medicinal chemistry letters.

[3]  H. Hamid,et al.  Synthesis of novel 8-hydroxy quinolin based 1,3,4-oxadiazoles and S-substituted 1,2,4-triazole derivatives and evaluation of their anti-inflammatory, analgesic, ulcerogenic and anti-microbial activities. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[4]  P. Badrinarayan,et al.  Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors , 2011, Journal of molecular modeling.

[5]  G. Narahari Sastry,et al.  Comparison of Computational Methods to Model DNA Minor Groove Binders , 2011, J. Chem. Inf. Model..

[6]  G. Narahari Sastry,et al.  Sequence, Structure, and Active Site Analyses of p38 MAP Kinase: Exploiting DFG-out Conformation as a Strategy to Design New Type II Leads , 2011, J. Chem. Inf. Model..

[7]  Priyanka Singh,et al.  Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives. , 2010, European journal of medicinal chemistry.

[8]  Ryan S. Davis,et al.  Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4. , 2010, Journal of medicinal chemistry.

[9]  G N Sastry,et al.  Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. , 2008, European journal of medicinal chemistry.

[10]  Thiam Hong Ang,et al.  Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents. , 2006, Antiviral research.

[11]  S. Gaonkar,et al.  Synthesis and antimicrobial studies of a new series of 2-[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]-5-substituted-1,3,4-oxadiazoles. , 2006, European journal of medicinal chemistry.

[12]  B. V. Ashalatha,et al.  Synthesis of Some New 2‐(6‐Methoxy‐2‐Naphthyl)‐ 5‐Aryl‐1,3,4‐Oxadiazoles as Possible Non‐steroidal Anti‐inflammatory and Analgesic Agents , 2005, Archiv der Pharmazie.

[13]  A. Zarghi,et al.  Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1,3,4-oxadiazoles. , 2005, Bioorganic & medicinal chemistry letters.

[14]  A. Cavalli,et al.  Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrroles related to donepezil. , 2001, Journal of medicinal chemistry.

[15]  I Silman,et al.  A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. , 2001, Biochemistry.

[16]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[17]  B. P. Doctor,et al.  Stable Complexes Involving Acetylcholinesterase and Amyloid-β Peptide Change the Biochemical Properties of the Enzyme and Increase the Neurotoxicity of Alzheimer’s Fibrils , 1998, The Journal of Neuroscience.

[18]  N. Inestrosa,et al.  Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. , 1997, Journal of molecular biology.

[19]  M. Rainer.  Galanthamine in Alzheimer’s Disease , 1997, CNS drugs.

[20]  A J Hopfinger,et al.  The rationale for E2020 as a potent acetylcholinesterase inhibitor. , 1996, Bioorganic & medicinal chemistry.

[21]  A. Nordberg,et al.  Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. , 1996, Dementia.

[22]  P. Powchick,et al.  Tacrine , 1995, The Lancet.

[23]  D. McTavish,et al.  Erratum to: Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease , 1994, Drugs & aging.

[24]  S. Clissold,et al.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. , 1987, Drugs.

[25]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[26]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[27]  M. Edin.  THE CHARTER OF THE COLLEGE OF PHYSICIANS. , 1845 .

[28]  X. Qian,et al.  Synthesis and quantitative structure-activity relationships of new 2,5-disubstituted-1,3,4-oxadiazoles. , 2001, Journal of agricultural and food chemistry.

[29]  D. McTavish,et al.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. , 1994, Drugs & aging.

[30]  J. Castaǹer,et al.  SDZ-ENA-713 , 1994 .